{"id":"251d3bc0-9f1e-5803-8d58-f4921926bf12","stable_key":"fd7915ff-856d-56c2-a118-4989693a7644:gingerols-ginger-warfarin-pk-null","predicate":"no_detected_change","statement":"Co-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"56a96423-90c7-571b-98cf-0746c3ee03a7","mechanism_event_label":"Co-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.","subject":{"id":"7fc47cae-306d-5878-990f-2c35b87dab6d","slug":"ginger-2005-warfarin-preparation","display_name":"Ginger product in the 2005 warfarin crossover study","entity_type_key":"small_molecule"},"object":{"id":"ec2202f1-48c4-5d68-9973-1df57397c542","slug":"human-warfarin-apparent-clearance","display_name":"Apparent oral clearance of warfarin enantiomers in humans","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"56a96423-90c7-571b-98cf-0746c3ee03a7","stable_key":"fd7915ff-856d-56c2-a118-4989693a7644:gingerols-ginger-warfarin-pk-null-event","event_type":"observed_relationship","label":"Co-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.","description":"Co-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7fc47cae-306d-5878-990f-2c35b87dab6d","slug":"ginger-2005-warfarin-preparation","display_name":"Ginger product in the 2005 warfarin crossover study","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ec2202f1-48c4-5d68-9973-1df57397c542","slug":"human-warfarin-apparent-clearance","display_name":"Apparent oral clearance of warfarin enantiomers in humans","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ee94b256-deeb-5795-8b6e-6e388576d464","slug":"warfarin","display_name":"Warfarin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Warfarin 25 mg once; ginger product at recommended study dose, exact herbal amount not in accessed abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Ginger for 7 days before and 7 days after warfarin","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation, not universally established human effects","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"12 healthy men in an open randomized three-way crossover study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Whole ginger rather than purified gingerols; a small healthy-volunteer null result cannot exclude interactions during chronic anticoagulation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Gingerols collection; each molecular form and experimental preparation remains explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"gingerols","display_name":"Gingerols","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"12 healthy men in an open randomized three-way crossover study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Co-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15801937/ DOI: 10.1111/j.1365-2125.2005.02322.x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral co-exposure","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma and coagulation measurements","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"152a38a2-e678-5844-920d-3777268a809c","evidence_kind":"source_excerpt","locator":"Lines 569-578","start_line":569,"end_line":578,"excerpt":"## gingerols-ginger-warfarin-pk-null\nCo-administered ginger product did not significantly change apparent clearance of either warfarin enantiomer in the crossover study.\nModel/species: 12 healthy men in an open randomized three-way crossover study\nTissue: Plasma and coagulation measurements\nExposure: Warfarin 25 mg once; ginger product at recommended study dose, exact herbal amount not in accessed abstract\nRoute: Oral co-exposure\nDuration: Ginger for 7 days before and 7 days after warfarin\nLimits: Whole ginger rather than purified gingerols; a small healthy-volunteer null result cannot exclude interactions during chronic anticoagulation.\nPrimary reference: Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15801937/ DOI: 10.1111/j.1365-2125.2005.02322.x\nAccess: Primary PubMed abstract.","model_system":"12 healthy men in an open randomized three-way crossover study","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact archived synthesis span with its primary citation; original paraphrase, not a claimed publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1107d60b-8e2d-55d7-8f5d-5612c49aa7dc","stable_key":"import-fd7915ff-856d-56c2-a118-4989693a7644","title":"Gingerols: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of thirteen primary research papers; study-specific PubMed/DOI links and limitations retained. Not publisher full text.","file_path":"","sha256":"96d1b7b04445eecd0eac1738e0c80cb6308509ecdfc3b5fc6be67ae2218cbb2b","revision_id":"de6e70ff-0e52-5c26-bd3a-54fca2085a86","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}